213763-81-6

Basic information

• Product Name: 2-cyclopropylmethyl-5-(4-methylsulfonyl)phenyl-4-phenyl-2H-pyridazin-3-one
• Synonyms: 2-cyclopropylmethyl-5-(4-methylsulfonyl)phenyl-4-phenyl-2H-pyridazin-3-one
• CAS NO: 213763-81-6
• Molecular Weight: 380.467
• Mol File: 213763-81-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-cyclopropylmethyl-5-(4-methylsulfonyl)phenyl-4-phenyl-2H-pyridazin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-cyclopropylmethyl-5-(4-methylsulfonyl)phenyl-4-phenyl-2H-pyridazin-3-one(213763-81-6)
• EPA Substance Registry System: 2-cyclopropylmethyl-5-(4-methylsulfonyl)phenyl-4-phenyl-2H-pyridazin-3-one(213763-81-6)

Safety Data

• Hazardous Substances Data: 213763-81-6(Hazardous Substances Data)

Upstream product

• 40487-93-2 (cyclopropylmethyl)hydrazine 
• 185147-17-5 5-Hydroxyrofecoxib 
• 213764-15-9 5-(4-methylsulfonyl)phenyl-4-phenyl-2H-pyridazin-3-one 
• 7051-34-5 cyclopropylcarbinyl bromide 
• 691005-66-0 (+/-)-5-bromo-4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one 
• 552865-15-3 4-bromo-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one 
• 552865-14-2 3-bromo-5-hydroxy-4-(4-methanesulfonyl-phenyl)-5H-furan-2-one 
• 552865-13-1 3-bromo-4-(4-methanesulfonyl-phenyl)-5H-furan-2-one 
• 162012-28-4 4-(4-(methylthio)phenyl)furan-2(5H)-one 
• 162011-90-7 rofecoxib 
• 98546-51-1 (4-thiomethoxyphenyl)boronic acid 
• 98-80-6 phenylboronic acid 

Downstream Products

• 213763-90-7 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone 

Relevant articles and documents

PYRIDAZINONES AS INHIBITORS OF CYCLOOXYGENASE-2

The invention encompasses the pyridazin-3-one compounds of formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a

Pyridazinones as inhibitors of cyclooxygenase-2

The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.